Xuanzhu Biopharmaceutical (02575) Publishes Monthly Return for October 2025

Bulletin Express

2025/11/06

Xuanzhu Biopharmaceutical Co., Ltd. (02575) announced its monthly return for the period ended 31 October 2025. According to the filing, the company’s total issued H shares remained at 160,701,996, and its unlisted shares remained at 357,245,794. No changes were recorded in either the number of issued shares or treasury shares.

The filing also shows that the total registered share capital was RMB 517,947,790 as of 31 October 2025. The H shares of the company were newly listed on the Main Board of The Stock Exchange of Hong Kong Limited on 15 October 2025, and the figures in the report reflect the status since its listing. No warrants, share options, or convertible securities were outstanding, and there were no repurchases or redemptions during the reporting period.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1126191866"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126191866\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126191866?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126191866","market":"us","top_or_hot":-1,"title":"Xuanzhu Biopharmaceutical (02575) Publishes Monthly Return for October 2025","media":"Bulletin Express","content":"<p>Xuanzhu Biopharmaceutical Co., Ltd. (02575) announced its monthly return for the period ended 31 October 2025. According to the filing, the company’s total issued H shares remained at 160,701,996, and its unlisted shares remained at 357,245,794. No changes were recorded in either the number of issued shares or treasury shares.</p>\n<p>The filing also shows that the total registered share capital was RMB 517,947,790 as of 31 October 2025. The H shares of the company were newly listed on the Main Board of The Stock Exchange of Hong Kong Limited on 15 October 2025, and the figures in the report reflect the status since its listing. No warrants, share options, or convertible securities were outstanding, and there were no repurchases or redemptions during the reporting period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biopharmaceutical (02575) Publishes Monthly Return for October 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biopharmaceutical (02575) Publishes Monthly Return for October 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-11-06 16:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Xuanzhu Biopharmaceutical Co., Ltd. (02575) announced its monthly return for the period ended 31 October 2025. According to the filing, the company’s total issued H shares remained at 160,701,996, and its unlisted shares remained at 357,245,794. No changes were recorded in either the number of issued shares or treasury shares.</p>\n<p>The filing also shows that the total registered share capital was RMB 517,947,790 as of 31 October 2025. The H shares of the company were newly listed on the Main Board of The Stock Exchange of Hong Kong Limited on 15 October 2025, and the figures in the report reflect the status since its listing. No warrants, share options, or convertible securities were outstanding, and there were no repurchases or redemptions during the reporting period.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"軒竹生物-B","start_time":0,"source_url":"","article_id":"1126191866","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126191866","pubTimestamp":1762418594,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Xuanzhu Biopharmaceutical Co., Ltd. (02575) announced its monthly return for the period ended 31 October 2025. According to the filing, the company’s total issued H shares remained at 160,701,996,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"轩竹生物制药(02575)公布2025年10月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"Xuanzhu Biopharmaceutical Co., Ltd. (02575) announced its monthly return for the period ended 31 October 2025. According to the filing, the company’s total issued H shares remained at 160,701,996, and its unlisted shares remained at 357,245,794. No changes were recorded in either the number of issued shares or treasury shares.\nThe filing also shows that the total registered share capital was RMB 517,947,790 as of 31 October 2025. The H shares of the company were newly listed on the Main Board of The Stock Exchange of Hong Kong Limited on 15 October 2025, and the figures in the report reflect the status since its listing. No warrants, share options, or convertible securities were outstanding, and there were no repurchases or redemptions during the reporting period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}